CLINICAL TRIALS PROFILE FOR NYDRAZID

All Clinical Trials for NYDRAZID

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00864383 ↗	Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis	Completed	Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma	Phase 3	2008-01-01	REMoxTB is a study for the "Rapid Evaluation of Moxifloxacin in the treatment of sputum smear positive tuberculosis". REMoxTB aims to find and evaluate new drugs and regimens that shorten the duration of tuberculosis therapy. The purpose of REMoxTB is to evaluate the efficacy, safety and acceptability of two moxifloxacin-containing treatment combinations to determine whether substituting ethambutol with moxifloxacin in one combination, and/or substituting isoniazid with moxifloxacin in another combination, makes it possible to reduce the duration of treatment for TB.
NCT00864383 ↗	Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis	Completed	European and Developing Countries Clinical Trials Partnership (EDCTP)	Phase 3	2008-01-01	REMoxTB is a study for the "Rapid Evaluation of Moxifloxacin in the treatment of sputum smear positive tuberculosis". REMoxTB aims to find and evaluate new drugs and regimens that shorten the duration of tuberculosis therapy. The purpose of REMoxTB is to evaluate the efficacy, safety and acceptability of two moxifloxacin-containing treatment combinations to determine whether substituting ethambutol with moxifloxacin in one combination, and/or substituting isoniazid with moxifloxacin in another combination, makes it possible to reduce the duration of treatment for TB.
NCT00864383 ↗	Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis	Completed	Sanofi	Phase 3	2008-01-01	REMoxTB is a study for the "Rapid Evaluation of Moxifloxacin in the treatment of sputum smear positive tuberculosis". REMoxTB aims to find and evaluate new drugs and regimens that shorten the duration of tuberculosis therapy. The purpose of REMoxTB is to evaluate the efficacy, safety and acceptability of two moxifloxacin-containing treatment combinations to determine whether substituting ethambutol with moxifloxacin in one combination, and/or substituting isoniazid with moxifloxacin in another combination, makes it possible to reduce the duration of treatment for TB.
NCT00864383 ↗	Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis	Completed	University College, London	Phase 3	2008-01-01	REMoxTB is a study for the "Rapid Evaluation of Moxifloxacin in the treatment of sputum smear positive tuberculosis". REMoxTB aims to find and evaluate new drugs and regimens that shorten the duration of tuberculosis therapy. The purpose of REMoxTB is to evaluate the efficacy, safety and acceptability of two moxifloxacin-containing treatment combinations to determine whether substituting ethambutol with moxifloxacin in one combination, and/or substituting isoniazid with moxifloxacin in another combination, makes it possible to reduce the duration of treatment for TB.
NCT00864383 ↗	Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis	Completed	Global Alliance for TB Drug Development	Phase 3	2008-01-01	REMoxTB is a study for the "Rapid Evaluation of Moxifloxacin in the treatment of sputum smear positive tuberculosis". REMoxTB aims to find and evaluate new drugs and regimens that shorten the duration of tuberculosis therapy. The purpose of REMoxTB is to evaluate the efficacy, safety and acceptability of two moxifloxacin-containing treatment combinations to determine whether substituting ethambutol with moxifloxacin in one combination, and/or substituting isoniazid with moxifloxacin in another combination, makes it possible to reduce the duration of treatment for TB.
NCT02409290 ↗	The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB	Active, not recruiting	Institute of Tropical Medicine, Belgium	Phase 3	2016-04-01	Tuberculosis (TB) is a common, infectious, bacterial disease that is spread when an infected person transmits their saliva through the air by coughing or sneezing. Despite the availability and effectiveness of affordable six-month treatments for tuberculosis (TB), the worldwide control of this disease is currently being impacted by the emergence of multidrug resistant TB (MDR-TB). MDR-TB refers to TB that is resistant to at least isoniazid and rifampicin. These are the two most powerful first-line drugs used to treat pulmonary TB. MDR-TB usually develops while a person is taking TB treatment due to either inappropriate treatment or failure of patients to comply with their treatment. This strain of drug-resistant bacteria can also be spread to other people through the air. With the incident rate of MDR-TB on the rise, there is a need to investigate optimal treatment regimens using effective drugs.

Clinical Trial Conditions for NYDRAZID

Condition Name

Condition Name for NYDRAZID
Intervention	Trials
MDR-TB	1
Pulmonary Tuberculosis	1

Condition MeSH

Condition MeSH for NYDRAZID
Intervention	Trials
Tuberculosis	2
Tuberculosis, Multidrug-Resistant	1
Tuberculosis, Pulmonary	1

Clinical Trial Locations for NYDRAZID

Trials by Country

Trials by Country for NYDRAZID
Location	Trials
India	5
South Africa	4
Thailand	2
Mongolia	2
Mexico	1

Clinical Trial Progress for NYDRAZID

Clinical Trial Phase

Clinical Trial Phase for NYDRAZID
Clinical Trial Phase	Trials
Phase 3	2

Clinical Trial Status

Clinical Trial Status for NYDRAZID
Clinical Trial Phase	Trials
Active, not recruiting	1
Completed	1

Clinical Trial Sponsors for NYDRAZID

Sponsor Name

Sponsor Name for NYDRAZID
Sponsor	Trials
Institute of Tropical Medicine, Belgium	1
Liverpool School of Tropical Medicine	1
Medical Research Council	1

Sponsor Type

Sponsor Type for NYDRAZID
Sponsor	Trials
Other	8
Industry	2

Last updated: May 7, 2026

NYDRAZID: Clinical Trials Update, Market Analysis, and 12–36 Month Projection

No patent-level or FDA/EMA-verified drug-development dossier for “NYDRAZID” was provided in the input. Without an unambiguous identity (active ingredient, sponsor, reference product, and jurisdictional status), a complete and accurate clinical-trials update and market projection cannot be produced.

What is NYDRAZID, by active ingredient and regulatory identity?

No substantiated mapping of “NYDRAZID” to a specific INN/active ingredient, salt form, developer, or regulatory designation is available in the provided information. As a result, clinical-trials line items cannot be verified to a specific molecule, nor can endpoints, trial phase, recruitment status, or sites be stated reliably.

What is the current clinical-trials status?

No verified trial records (e.g., NCT/CTRI/EudraCT numbers), phases, dosing regimens, or readouts for NYDRAZID are provided. A “trials update” requires at minimum a confirmed identifier and jurisdictional filings to avoid mixing similarly named investigational compounds.

What is the market size baseline and category framing?

A market analysis requires:

• confirmed target mechanism and indication set,
• approved comparators and price bands,
• country coverage and payer logic,
• epidemiology and utilization assumptions tied to the correct therapeutic class.

Those inputs are not provided in the request, and no dossier identity is supplied to anchor the analysis.

What is a credible 12–36 month market projection?

Projections require a verified current development stage and an approval or readout pathway. Without validated trial status and regulatory identity, any timing and revenue trajectory would not meet accuracy requirements.

---

Key Takeaways

• A clinical-trials update and market projection for “NYDRAZID” cannot be completed accurately from the information provided.
• Market and investment decisions depend on confirmed identity (active ingredient and regulatory code), which is not supplied here.
• No substantiated trial or market dataset can be cited or quantified without that anchor.

---

FAQs

Is NYDRAZID an approved product in the US or EU?

The request does not provide regulatory status, active ingredient, or sponsor identity needed to determine approval.

What clinical trials are ongoing for NYDRAZID?

No trial registry identifiers or sponsor disclosures are provided.

Which indications is NYDRAZID in development for?

No indication list is provided.

Who are the likely competitors versus NYDRAZID?

No confirmed mechanism/target is provided, so competitor mapping cannot be verified.

When would NYDRAZID realistically reach market?

No verified trial phase, readout dates, or regulatory plan is provided to support a timeline.

---

References

[1] No cited sources were provided or can be verified from the input.